Company / Return on Assets (ROA)
Spyre Therapeutics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-20.0%
FY2025
5-year range
-113.7% / -20.0%
FY2021-FY2025
Trend
+41.6%
vs FY2024
Sector context
#100 of 213
Health Care
What the data says
At -20.0%, Spyre Therapeutics, Inc.'s return on assets (roa) ranks #100 of 213 in the Health Care sector. Return on Assets (ROA) has increased for 3 consecutive years, from -113.7% in FY2022 to -20.0% in FY2025.
Based on SEC 10-K filings.
-20.0% in FY2025 with a 5-year CAGR of +7.5%.
Improved from -99.1% to -20.0% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +93.8pp
- 5-Year Change
- +7.5pp
- 10-Year Change
- -
Sector benchmark
#100 of 213 in Health CareTop 47% of 213This company -20.0% Sector average -24.1%
▼
+17.4% above sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s return on assets (roa) has grown for 3 consecutive years.
- In FY2025, return on assets (roa) increased 41.6% year-over-year.
- Currently 4.2pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -20.0% | +41.6% |
| FY2024 | -34.2% | +65.5% |
| FY2023 | -99.1% | +12.8% |
| FY2022 | -113.7% | -89.9% |
| FY2021 | -59.9% | -118.1% |
| FY2020 | -27.4% | +16.2% |
| FY2019 | -32.7% | -17.3% |
| FY2018 | -27.9% | +42.5% |
| FY2017 | -48.6% | -50.1% |
| FY2016 | -32.4% | -10.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026